Because the decision of where to treat breast cancer has never carried more weight, patients today are navigating a disease whose global scale is still expanding. In 2022, 2.3 million new diagnoses were recorded and nearly 670,000 lives were lost — numbers that the World Health Organization projects will grow by almost 40% by 2050 (annual cases are expected to surpass 3.2 million). A woman in a high-income country faces roughly a 1 in 12 lifetime risk to develop breast cancer. And in low-income regions, that figure drops to 1 in 27 [1].
That gap in risk is also a gap in access — which is precisely why breast cancer treatment in Germany draws patients seeking not just care, but outcomes. German clinics combine early and accurate diagnosis with minimally invasive techniques, breast conserving surgery, reconstruction, systemic therapy, and radiation therapy into a single coordinated system. The result is not a collection of the latest treatment methods but an integrated approach where each intervention is designed to reinforce the next — and where survival rates reflect that design.
Conventional Breast Cancer Treatment in Germany
What makes conventional breast cancer treatment in Germany consistently effective is not access to superior technology — it is the clinical logic that determines how that technology is applied. Surgery, radiation, hormone therapy, and systemic therapy — all are calibrated to each patient. This means no two treatment plans follow the same sequence. Breast-conserving surgery is prioritized wherever oncologically sound, because the tissue preserved today shapes the recovery possible tomorrow. When reconstruction becomes necessary, German clinics plan it in advance. Active oncology research (e.g. trials of cancer vaccines and emerging systemic agents) is carried out alongside conventional care and changes the boundary between what is standard and what is new.
Surgical Treatment For Breast Cancer
Surgical treatment of a breast tumor in Germany aims to achieve the complete removal of atypical tissues, including the primary tumor, tumor tissues, and any potentially affected lymph nodes, as well as the correction of postoperative cosmetic defects. If necessary, a surgical procedure for tumor removal is immediately supplemented with breast reconstruction, which avoids repeated anesthesia and improves quality of life for breast cancer patients.
The modifications of organ-preserving surgical procedures include cryoablation, sectoral resection with lymphadenectomy, tumorectomy, and lumpectomy. These types of breast cancer surgery in Germany are typically performed to remove neoplasms less than 25 mm in size. As a rule, surgeons excise the tumor along with several nearby lymph nodes, which helps prevent recurrence of the malignant process. To improve accuracy, German clinics use advanced technologies such as the FDA-approved MarginProbe device, which detects residual tumor cells in the surgical field and ensures complete removal.
Radical mastectomy in Germany is reserved for cases when invasive breast cancer has spread to the pectoral muscles and axillary lymph nodes. In other situations, surgeons prefer more sparing modifications of mastectomy:
- Skin-sparing mastectomy, which facilitates subsequent autologous breast reconstruction
- Nipple-sparing mastectomy, which additionally preserves the nipple and areola
- Simple mastectomy, which preserves axillary lymph nodes and pectoral muscles
The choice between these surgical modifications depends on tumor size, multifocality, lymph node status, and the patient's reconstruction priorities.
Booking Health forwards the complete preoperative imaging record to the German surgical team before the consultation, so the surgeon's first discussion of the case is a procedure planning session built on current measurements, not on a staging summary.
CHECK IF A BETTER SOLUTION EXISTS FOR YOURadiation Therapy For Breast Cancer
German clinics apply multiple modes of radiation therapy as part of breast cancer treatment in Germany:
- Preoperative radiotherapy (intensive or delayed) can destroy cancer cells located on the periphery of the tumor, reducing the risk of spreading malignant cells to distant parts of the body. A delayed course may also shrink the tumor, making breast cancer surgery possible in cases previously considered inoperable.
- Postoperative radiotherapy performed 2–4 weeks after surgical treatment, targets preserved lymph nodes (supraclavicular or parasternal) and reduces the risk of disease progression.
- Intraoperative radiotherapy (intrabeam technique) is used during organ-preserving operations, irradiating the tumor bed and axillary lymph nodes immediately after tumor removal.
- Independent radiation therapy may be chosen when surgical treatment is contraindicated or at the patient’s request.
- Interstitial radiotherapy can complement external radiation therapy for nodular breast carcinomas, minimizing damage to surrounding healthy tissues.
If indicated, whole radiation therapy for breast cancer can be replaced by partial breast irradiation, reducing the number of sessions and potential side effects.
Chemotherapy For Breast Cancer
Chemotherapy for breast cancer remains one of the most widely used systemic treatments in Germany. It can be given in two ways:
- Neoadjuvant chemotherapy (before surgery) reduces tumor size, allowing surgeons to perform breast-conserving surgery instead of mastectomy
- Adjuvant chemotherapy (after surgery) helps destroy cancer cells that may remain in the body and prevents recurrence
German oncologists rely on modern agents, which show the best results in trials. Postmenopausal women with ER-positive tumors often respond well to adjuvant chemotherapy, sometimes in combination with hormone therapy.
To choose the most effective systemic therapy regimen, German clinics employ prognostic genomic testing:
- Oncotype Dx™ (analysis of 21 genes to assess relapse risk)
- MammaPrint® (expression profile of 70 genes)
- PAM50 test (50 genes associated with cancer recurrence)
These advanced technologies support personalized cancer care and help doctors design systemic therapy that minimizes side effects while maximizing control over tumor growth.
Genomic testing results — Oncotype Dx, MammaPrint, or PAM50 — are the data points that most directly determine which adjuvant chemotherapy regimen, if any, is appropriate. These tests are expensive and not routinely performed in all healthcare systems.
For patients arriving without genomic profiling, Booking Health identifies the gap and arranges the relevant testing in Germany before the systemic therapy protocol is finalized.
A chemotherapy regimen assigned without genomic risk stratification may be unnecessarily aggressive or insufficiently targeted — either outcome is avoidable.
GET A SECOND OPINION FOR YOUR CASEHormone Therapy For Breast Cancer
Because roughly 50–70% of breast carcinomas are driven by estrogen and progesterone, hormone therapy is not a supplementary option in German breast cancer care — it is a primary line of attack for the majority of patients. German oncologists evaluate receptor expression before prescribing any hormonal intervention, which means treatment is directed at the tumor's actual biology rather than applied on assumption. This precision is what allows hormone therapy to suppress tumor growth without the collateral damage that less targeted approaches produce.
Three hormonal strategies form the clinical toolkit, each targeting a different point in the estrogen-driven growth chain:
- Antiestrogens occupy the hormonal receptors that tumor cells rely on, blocking the signal that would otherwise drive carcinoma growth in estrogen-sensitive disease — starving the tumor of the biological instruction it needs to advance.
- Aromatase inhibitors work upstream, reducing estrogen synthesis before it ever reaches the receptor, which is why they are the preferred choice for postmenopausal women whose estrogen originates in peripheral tissue rather than the ovaries.
- Androgens suppress estrogen through a separate biochemical route and are reserved for metastatic disease that has already exhausted the first two lines of hormonal intervention.
German clinics confirm estrogen and progesterone receptor status through immunohistochemical testing before any of these therapies begins — not as a formality, but because a hormonal treatment prescribed without that confirmation is not personalized oncology. It is a guess dressed as a protocol.
Innovative Breast Cancer Treatment in Germany
Patients who arrive in Germany with aggressive or treatment-resistant disease are not arriving because conventional options are unavailable elsewhere — they are arriving because those options have already failed them. Triple-negative breast cancer and invasive forms that no longer respond to first-line treatment demand a different category of intervention: new therapies that bypass the resistance mechanisms conventional drugs cannot overcome. Targeted therapy, dendritic cell vaccination, and interventional oncology procedures like TACE have been integrated into German clinical practice because each reaches the disease through a mechanism that standard systemic treatment was never designed to use.
Targeted Therapy for Breast Cancer in Germany
What separates targeted therapy from conventional treatments is not potency — it is address. Standard chemotherapy moves through the entire body; targeted drugs are engineered to block the specific molecular pathways that a given tumor depends on for survival, which means the therapy concentrates its effect where the disease actually lives. HER2-positive and hormone receptor-positive tumors are particularly vulnerable to this approach, often treated with targeted agents alongside adjuvant chemotherapy or hormone therapy to close the biological gaps no single drug covers alone.
Research protocols running inside German clinics extend this further, testing new agents against tumor tissue that has developed resistance to existing targeted drugs. For patients who have reached that point, access to these trials is not a secondary option — it is often the intervention with the highest probability of changing their outcome.
Dendritic Cell Therapy and Personalized Immunotherapy for Breast Cancer in Germany
When Ralph Steinman received the Nobel Prize in Physiology or Medicine in 2011 for identifying the role dendritic cells play in immune regulation [5], the recognition did more than honor a discovery — it reframed what oncologists believed the body’s immune system could be trained to do. Dendritic cells carry tumor-specific signals to the immune system's effector cells, teaching them to recognize malignancy and act against it — a function that, properly harnessed, turns the patient's own biology into a treatment mechanism. German clinics have built vaccination strategies around this principle, designing protocols calibrated to the specific antigenic profile of each patient's tumor rather than to a generalized immune target.
For patients with triple-negative breast cancer, this matters in a way it does not for other subtypes — because where hormone therapy finds no receptor and HER2-targeted agents find no target, a well-activated immune cells response still has something to work with.
Triple-negative breast cancer — the subtype for which DC vaccination is most clinically significant precisely because targeted and hormone therapies are inapplicable — has the most dynamic antigen landscape. The tumor's surface proteins shift with each treatment line, meaning that a vaccine loaded from biopsy material obtained before prior chemotherapy may not reflect the tumor's current antigenic profile.
Booking Health's pre-treatment case review assesses whether current tissue or liquid biopsy is available to serve as the antigen source, before the program at the German center is confirmed.
BOOK CONSULTATIONTACE for Breast Cancer
TACE is an interventional oncology technique increasingly applied in the treatment of metastatic breast cancer in Germany. The procedure delivers chemotherapy drugs directly into the blood vessels feeding the tumor, while simultaneously blocking these vessels to limit tumor growth. By concentrating the drug inside the malignant process, TACE destroys cancer cells locally while reducing systemic side effects.
German clinics use TACE in selected cases where standard systemic therapy is less effective, especially in metastatic disease that has spread to the liver. As part of innovative breast cancer treatment in Germany, TACE complements other advanced therapies, offering new hope for cancer patients who require personalized and minimally invasive techniques.
Regional Chemotherapy for the Treatment of Breast Cancer
For patients whose tumors have resisted systemic treatment, the limiting factor is rarely the drug — it is the dose the rest of the body can tolerate. Regional chemotherapy in Germany solves this problem not by finding a stronger agent, but by changing where and how the agent is delivered. Isolated thoracic perfusion confines chemotherapy exclusively to the chest region, which means concentrations that would be toxic if circulated systemically can reach the tumor directly, at the levels actually required to act on it.
The procedure works through temporary vascular isolation. Balloon catheters are inserted through vessels in the groin and threaded upward to the aorta and vena cava; once positioned beneath the diaphragm, the balloons inflate and separate the chest's circulation from the rest of the body. For 15 minutes, concentrated chemotherapy circulates only within this isolated zone — blood carrying the drugs directly to the tumor through its own natural supply. When perfusion ends, hemofiltration cleans the blood for 45 minutes before the balloons deflate and normal circulation resumes.
Breast tumors are particularly well-suited to this approach because of their characteristically strong blood supply, which becomes the delivery mechanism rather than an obstacle. Germany's specialized centers have refined isolated thoracic perfusion most extensively for locally relapsed disease — cases where the cancer has returned in a region already treated, often causing pain or functional distress that systemic options have failed to control.
Electrochemotherapy in Breast Cancer
The principle behind electrochemotherapy is that chemotherapy's limitations are often not pharmacological — they are structural. Cancer cell membranes restrict drug absorption under standard delivery conditions; electrochemotherapy removes that restriction by using brief electrical pulses to open temporary pores in the membrane, increasing cellular drug uptake by a factor of 80. Patients receive general anesthesia while electrode needles are positioned around the tumor at 2.5–3 centimeter intervals, and a computer synchronizes the electrical pulses with the heartbeat to eliminate cardiac interference — because the precision of timing here is what separates a controlled procedure from an uncontrolled one.
During the procedure, concentrated chemotherapy is delivered through arterial infusion or isolated thoracic perfusion while the electrical pulses hold the membrane open. It takes minutes. The combination of regional delivery and enhanced cellular absorption reaches drug concentrations inside the tumor that systemic therapy cannot produce — which is precisely why this approach is used for resistant disease rather than as a first-line option.
The clinical evidence for what this makes possible is difficult to dismiss: among 14 patients with locally relapsed triple-negative breast cancer, tumors averaging 7.6 centimeters in size, 13 achieved measurable shrinkage and 4 became surgical candidates [6]. Every one of those women had already failed multiple prior treatments — which means electrochemotherapy was not competing with untested alternatives. It was succeeding where everything else had not.
The cost of electrochemotherapy varies by center, and electrochemotherapy cost reflects specialized equipment needs. However, electro-chemotherapy may avoid major surgery while controlling resistant disease.
Leading Hospitals for Breast Cancer and the Cost of Treatment in Germany
Leading university hospitals for breast cancer treatment based on the statistics and success rates for breast cancer treatment in Germany, are:
- University Hospital Tuebingen, Department of Adult and Pediatric Gynecology, Mammology, Obstetrics
- University Hospital Ulm, Department of Obstetrics, Adult and Pediatric Gynecology
For patients looking at breast cancer programs cost, breast cancer treatment in Germany has one of the most competitive prices in developed healthcare systems. Compared to the United States and the United Kingdom, German hospitals provide high-quality care at significantly lower costs, without compromising results.
Cost of Breast Cancer Treatment: Germany vs UK vs USA
| Treatment Method | Germany | United Kingdom | United States |
|---|---|---|---|
| Breast-conserving surgery (lumpectomy + sentinel node biopsy) | €14,300-€23,500 | €35,000-€55,000 | €65,000-€85,000 |
| Breast reconstruction after mastectomy | €14,200-€23,700 | €40,000-€60,000 | €70,000-€100,000 |
| Chemotherapy (full course) | €80,000-€150,000 | €90,000-€165,000 | €100,000-€180,000 |
| Radiation therapy (standard 25-30 sessions) | €28,000-€42,000 | €35,000-€65,000 | €40,000-€80,000 |
As is evident, breast cancer treatment cost in Germany, including the cost of breast cancer treatment is the fourth stage in Germany, is 30-50% lower compared to the US while maintaining world-class medical quality. In addition, compared to the UK, German clinics provide faster access to treatment without long waiting lists.
Germany's published rates are already the most favorable in the table — and they become more favorable still for patients coordinating through Booking Health, whose direct institutional agreements eliminate the fee clinics apply to international patients.
Invoice control during the program and return of unspent funds after its conclusion ensure the financial relationship remains transparent from commitment to completion.
What's Included in the Price of Breast Cancer Treatment
The breast cancer treatment package in Germany usually includes:
- Diagnostics: mammography, ultrasound, MRI, PET-CT, biopsy
- Surgery: breast-conserving surgery, mastectomy, or reconstructive surgery
- Medications: chemotherapy drugs, targeted therapy, and hormonal treatment
- Hospital stay: accommodation, nursing care, and meals
- Follow-up therapy: check-ups, rehabilitation, and aftercare
Optional services include advanced oncoplastic surgery, rehabilitation programs, and second opinions from top specialists in the best hospitals for breast cancer treatment in Germany.
Breast Cancer Treatment Success Story in Germany
Anna Scoric traveled from Ukraine to Germany at a moment when the diagnosis of breast cancer had narrowed her choices to one that mattered most: where she would have the best chance. She chose Marien Hospital Düsseldorf and the care of Prof. Dr. Giagounidis — and beginning in February 2022, her treatment combined chemotherapy, radiation therapy, and structured follow-up examinations into a plan that moved with her rather than around her.
What made the difference was not any single intervention but the coordination holding them together. When a COVID infection disrupted her schedule, medical tourism coordinators Maria Stern and Natalie Korner absorbed the disruption and restructured what needed restructuring — because in a treatment plan where timing affects outcome, an unmanaged gap is not an inconvenience. Professional interpreters supported Anna inside the clinic and beyond it, in the practical moments of daily life that accumulate into either confidence or exhaustion depending on how they are handled.
Anna's account of her experience returns consistently to one observation: that precise diagnosis, innovative therapy, and genuine personal attention did not exist as separate features of her care — they functioned as a single environment. For a patient who had crossed a border in the middle of a war to pursue treatment, that environment was not a comfort. It was the condition that made recovery possible.
Anna's experience reflects something that holds true across cases: when the right environment meets the right treatment, patients stop enduring and start recovering. That shift looks different for every patient — for some it means access to better surgery, for others it means discovering that a procedure exists which their home system never mentioned. Nela Malacova, a Czech patient with stage IV breast cancer and rapidly growing liver metastases, had exhausted her local options and was facing another round of systemic chemotherapy when Booking Health showed her that TACE existed: a procedure that sends chemotherapy straight into the tumor's blood supply, leaving everything else untouched. The side effects lasted days. Her recovery took less than two weeks. Watch the video below to hear what that difference meant to her.
VIDEO
Why I Refused Systemic Chemo: Finding Hope with Targeted Tumor Treatment TACE in Germany
TACE
BOOK CONSULTATION
Booking Health's involvement does not end at the clinic door or after the first treatment cycle. For multi-cycle programs, the personal coordinator remains the active link between the patient, the clinic, and any circumstances that require adjustment.
That continuity is not incidental to the outcome — it is part of what makes the outcome achievable.
Get full treatment coordination supportInternational Cancer Care: Patient Stories with Booking Health
A Medical Journey: Every Step of the Way with Booking Health
Finding the best treatment strategy for your clinical situation is a challenging task. Being already exhausted from multiple treatment sessions, having consulted numerous specialists, and having tried various therapeutic interventions, you may be lost in all the information given by the doctors. In such a situation, it is easy to choose a first-hand option or to follow standardized therapeutic protocols with a long list of adverse effects instead of selecting highly specialized innovative treatment options.
To make an informed choice and get a personalized cancer management plan, which will be tailored to your specific clinical situation, consult medical experts at Booking Health. Being at the forefront of offering the latest medical innovations for already 12 years, Booking Health possesses solid expertise in creating complex management programs in each individual case. As a reputable company, Booking Health offers personalized treatment plans for breast cancer with direct clinic booking and full support at every stage, from organizational processes to assistance during treatment.
We provide:
- Assessment and analysis of medical reports
- Development of the medical care program
- Selection of a suitable treatment location
- Preparation of medical documents and forwarding to a suitable clinic
- Preparatory consultations with clinicians for the development of medical care programs
- Expert advice during the hospital stay
- Follow-up care after the patient returns to their native country after completing the medical care program
- Taking care of formalities as part of the preparation for the medical care program
- Coordination and organization of the patient's stay in a foreign country
- Assistance with visas and tickets
- A personal coordinator and interpreter with 24/7 support
- Transparent budgeting with no hidden costs
Health is an invaluable aspect of our lives. Delegating management of something so fragile yet precious should be done only to experts with proven experience and a reputation. Booking Health is a trustworthy partner who assists you in pursuing stronger health and a better quality of life. Contact our medical consultant to learn more about the possibilities of personalized treatment with innovative methods for breast cancer with leading specialists in this field.
Booking Health holds ISO 9001 quality certification, reflecting well-established processes and strict quality control at every stage of the treatment journey — not just at the initial consultation, but throughout.
Frequently Asked Questions of Our Patients About Breast Cancer Treatment in Germany
Germany's gynecological oncology centers cover the full spectrum of breast cancer intervention — surgery, breast-conserving procedures, chemotherapy, radiation therapy, targeted therapy, hormone therapy, and innovative options including IORT and immunotherapy. Each patient receives a treatment plan built around her specific disease profile rather than a standard institutional sequence.
Early-stage disease in Germany is treated as an opportunity for precision, not simply for intervention. The focus falls on accurate diagnosis, organ-preserving procedures like lumpectomy and breast-conserving surgery, and targeted systemic therapy calibrated to minimize recurrence while protecting the patient's quality of life — because what is preserved at this stage shapes everything that follows.
Breast-conserving surgery is not only available in Germany — it is the preferred surgical approach wherever oncologically viable. Lumpectomy and sectoral resections, frequently combined with intraoperative radiation therapy, allow surgeons to remove the tumor while protecting the surrounding healthy tissue that conventional mastectomy would sacrifice.
IORT delivers a focused, high-dose radiation treatment directly to the tumor bed at the moment of surgery — before the wound closes, while the target zone is most precisely defined. German clinics offer this as a standard component of breast-conserving surgery, eliminating the delay between surgical and radiation treatment that creates recurrence risk in conventional sequencing.
Chemotherapy is prescribed when the tumor's biology calls for it, not as a default. Patients with hormone receptor-positive or early-stage disease may be treated effectively through hormone therapy or targeted systemic agents alone — because applying chemotherapy where it is not indicated does not improve outcomes. It only adds toxicity.
German oncologists use HER2-directed agents for HER2-positive disease, PARP inhibitors for triple-negative breast cancer, and a range of other systemic agents engineered to act on the tumor's specific molecular vulnerabilities. The defining characteristic of targeted therapy in Germany is that the drug follows the diagnosis — not the other way around.
Immunotherapy is available in Germany for selected patients, with triple-negative breast cancer representing the subtype where it is most consequential — precisely because this form of the disease does not respond to hormone therapy or HER2-targeted drugs. German clinics combine immunotherapy with systemic treatment to build a response the tumor's immune evasion mechanisms have not yet learned to counter.
The advantages are structural, not promotional. Modern clinics, experienced oncologists, advanced surgical techniques, and access to innovative therapies are not exceptional features in Germany — they are the baseline from which treatment is built. For international patients, comprehensive coordination of care is built into that same baseline.
Booking Health manages the logistical architecture that makes treatment abroad viable: medical visas, translation services, appointments with experienced oncologists, and direct coordination with leading German hospitals. For patients navigating a foreign healthcare system while managing a serious diagnosis, that infrastructure is not a convenience — it is what makes the treatment accessible.
Figures reflect the stage of disease, the therapies required, and whether reconstruction is part of the plan. Booking Health provides transparent, personalized cost estimates based on each patient's medical documentation.
German clinics are structured to receive international patients — with medical visa support, professional translation, and care pathways designed for patients who are managing treatment far from home. The clinical standard does not change based on the patient's origin; the coordination infrastructure exists to ensure it doesn't have to.
Hormone therapy in Germany targets hormone receptor-positive disease through antiestrogens, aromatase inhibitors, or androgens — each selected based on the patient's receptor profile, menopausal status, and disease stage. It is frequently combined with surgery or targeted therapy, because hormonal control of tumor growth is most effective when it operates alongside interventions addressing what hormone suppression alone cannot reach.
A second opinion in Germany means more than a review of existing conclusions — it means experienced oncologists examining tumor tissue directly, reassessing staging, and evaluating whether the proposed treatment plan reflects the most current evidence. Booking Health coordinates these consultations, including the documentation transfer and specialist access that make the opinion clinically meaningful rather than purely confirmatory.
Surgery begins at approximately €25,000, chemotherapy from around €80,000, and radiation therapy from €28,000 — with the final figure shaped by disease stage, tumor type, chosen hospital, and whether reconstruction is included. These are starting points, not fixed prices; a personalized estimate requires review of the patient's specific medical profile.
The price covers the full clinical package: advanced diagnostics, surgical treatment, chemotherapy or hormonal medications, hospital stay, and post-treatment follow-up care. What patients are paying for is not a procedure — it is a coordinated treatment arc from diagnosis through recovery.
The variables that determine final cost are clinical, not administrative: disease stage and tumor type, the aggressiveness of the cancer, the hospital and specialists selected, the combination of therapies required, and whether breast reconstruction surgery is incorporated into the plan. Each of these factors shifts the complexity of care — and cost follows complexity.
Germany offers treatment costs that are substantially lower than in the United States and comparable to or below those in the United Kingdom — with the additional advantage of shorter waiting times. The differential is not a function of lower standards; it reflects a healthcare system that has not built the administrative cost layers that drive prices upward in other high-income countries.
Early-stage treatment typically requires organ-preserving surgery combined with radiation — a far less resource-intensive pathway than advanced-stage care involving mastectomy, chemotherapy, and reconstruction. The cost difference is real, but the more important implication is clinical: early diagnosis does not just reduce the financial burden of treatment. It expands the options available for managing the disease.
Request a coordinated estimate through Booking Health — which works with leading hospitals to provide pricing that reflects the patient's actual diagnosis rather than a generic category. Transparency at this stage matters because treatment planning and financial planning need to move together.
German clinics charge 30–50% less than US hospitals on average, while maintaining equivalent clinical standards and offering faster access to treatment than the UK system typically allows. For international patients, that gap represents not just a financial decision but a practical one — because access delayed is often access denied.
Choose treatment abroad and you will for sure get the best results!
Sources:
01. World Health Organization. Breast cancer. https://www.who.int/news-room/fact-sheets/detail/breast-cancer
02. Nicola L Barclay, Edward Burn, Antonella Delmestri et al. Trends in incidence, prevalence, and survival of breast cancer in the United Kingdom from 2000 to 2021. Sci Rep. 2024 Aug 17;14:19069. doi: 10.1038/s41598-024-69006-1. [DOI] [PMC free article]
03. Feng Ye, Saikat Dewanjee, Yuehua Li, Niraj Kumar Jha et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Front Endocrinol (Lausanne). Mol Cancer. 2023 Jul 6;22:105. doi: 10.1186/s12943-023-01805-y. [DOI] [PMC free article]
04. Kyu-Won Lee, Judy Wai Ping Yam, Xiaowen Mao. Dendritic Cell Vaccines: A Shift from Conventional Approach to New Generations. Cells. 2023 Aug 25;12(17):2147. doi: 10.3390/cells12172147. [DOI] [PMC free article]
05. Nobel Prize. The Nobel Prize in Physiology or Medicine 2011 – Ralph Steinman. https://www.nobelprize.org/prizes/medicine/2011/steinman/facts/
06. Aigner K, Selak E, Pizon M, et al. Arterial infusion and isolated perfusion in combination with reversible electroporation for locally relapsed unresectable breast cancer. Cancers (Basel). 2024;16(23):3991. doi:10.3390/cancers16233991. [DOI]
Read:
01. Dendritic Cell Therapy for Breast Cancer
02. Immunotherapy for breast cancer in Germany
03. Comprehensive Guide to Breast Cancer Treatment: New and Standard Treatment Options
